Showing results (21-30 of 45) with videos related to
Sort By:
Pageof 5
Cephalalgia : an International Journal of Headache|December 24, 2013
Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized studyVincenzo Tullo, Fabio Valguarnera, Piero Barbanti, et al.Brain Sciences|July 27, 2024
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life StudyPiero Barbanti, Bianca Orlando, Gabriella Egeo, et al.Journal of Neurology|February 11, 2024
Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.The Journal of Headache and Pain|April 10, 2022
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 29, 2015
Early (≤ 1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group studyGianni Allais, Gennaro Bussone, Vincenzo Tullo, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 29, 2014
Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without auraGianni Allais, Vincenzo Tullo, Pietro Cortelli, et al.The Journal of Headache and Pain|December 19, 2021
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort studyFabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 16, 2025
The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectivenessFabrizio Vernieri, Anna Ambrosini, Marco Bartolini, et al.The Journal of Headache and Pain|January 29, 2010
Headache, anxiety and depressive disorders: the HADAS studyEttore Beghi, Gennaro Bussone, Domenico D'Amico, et al.Journal of Neurology|January 25, 2025
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE studyPiero Barbanti, Cinzia Aurilia, Paola Torelli, et al.Pageof 5